EA200300172A1 - Метод обезболивания - Google Patents

Метод обезболивания

Info

Publication number
EA200300172A1
EA200300172A1 EA200300172A EA200300172A EA200300172A1 EA 200300172 A1 EA200300172 A1 EA 200300172A1 EA 200300172 A EA200300172 A EA 200300172A EA 200300172 A EA200300172 A EA 200300172A EA 200300172 A1 EA200300172 A1 EA 200300172A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pain
anesthesia method
formulation
dissolved
blocks
Prior art date
Application number
EA200300172A
Other languages
English (en)
Other versions
EA004870B1 (ru
Inventor
Квингбин Донг
Фрэнк Хэйконг Шам
Original Assignee
Уэкс Медикал Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уэкс Медикал Лимитед filed Critical Уэкс Медикал Лимитед
Publication of EA200300172A1 publication Critical patent/EA200300172A1/ru
Publication of EA004870B1 publication Critical patent/EA004870B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Laser Surgery Devices (AREA)

Abstract

Настоящее изобретение относится к методу анальгезии млекопитающего, испытывающего боль, посредством систематического введения эффективного количества состава, в основном включающего соединение, блокирующее натриевый канал, растворенного в подходящей фармацевтической среде, в целях облегчения боли.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300172A 2000-09-18 2001-09-11 Способ обезболивания EA004870B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB001245171A CN1284536C (zh) 2000-09-18 2000-09-18 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
PCT/CN2001/001391 WO2002022129A1 (en) 2000-09-18 2001-09-11 A method of analgesia

Publications (2)

Publication Number Publication Date
EA200300172A1 true EA200300172A1 (ru) 2003-12-25
EA004870B1 EA004870B1 (ru) 2004-08-26

Family

ID=4590472

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300172A EA004870B1 (ru) 2000-09-18 2001-09-11 Способ обезболивания

Country Status (26)

Country Link
US (1) US6407088B1 (ru)
EP (3) EP1320369B1 (ru)
JP (1) JP2004508404A (ru)
KR (2) KR100891568B1 (ru)
CN (1) CN1284536C (ru)
AT (2) ATE447959T1 (ru)
AU (1) AU2002213785A1 (ru)
BG (1) BG107690A (ru)
BR (1) BR0113961A (ru)
CA (1) CA2421562C (ru)
DE (1) DE60140466D1 (ru)
EA (1) EA004870B1 (ru)
EE (1) EE200300106A (ru)
ES (1) ES2435463T3 (ru)
HR (1) HRP20030202A2 (ru)
HU (1) HUP0302677A3 (ru)
IL (1) IL154342A0 (ru)
IS (1) IS6719A (ru)
MX (1) MXPA03002389A (ru)
NO (1) NO323960B1 (ru)
PL (1) PL360616A1 (ru)
SK (1) SK3732003A3 (ru)
UA (1) UA76960C2 (ru)
WO (1) WO2002022129A1 (ru)
YU (1) YU17103A (ru)
ZA (1) ZA200301852B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU738197C (en) 1997-04-22 2002-05-16 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
EP1443932B1 (en) * 2001-11-15 2012-12-26 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
WO2004013637A1 (en) * 2002-08-01 2004-02-12 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
WO2004066990A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
CA2821239C (en) * 2004-05-07 2016-04-12 Phytotox Limited Phycotoxins and uses thereof
AU2005244096B2 (en) * 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
CN100363006C (zh) * 2004-08-20 2008-01-23 厦门朝阳生物工程有限公司 一种戒毒制剂及其制备方法
EP1799219A1 (en) * 2004-09-21 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
US20100075992A1 (en) * 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
EP1690541A1 (en) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency
CA2597101A1 (en) * 2005-02-11 2006-08-17 Wex Pharmaceuticals, Inc. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1714655A1 (en) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
CA2619856A1 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
WO2007025213A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the management of musculoskeletal pain
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1844781A1 (en) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of preterm labor
WO2007110220A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
EP1844783A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel - subunit Nav1.6
EP1844782A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
EP2012774A1 (en) 2006-03-27 2009-01-14 Wex Pharmaceuticals, Inc Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
EP1882692A1 (en) * 2006-07-28 2008-01-30 Wex Pharmaceuticals Inc. Dimethano-[1,3]dioxocino[6,5-D]pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain
BRPI0814409A2 (pt) * 2007-07-06 2014-10-14 Nuon Therapeutics Inc Tratamento de dor neuropática
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US20120034296A1 (en) * 2009-04-08 2012-02-09 Massachusetts Institute Of Technology Prolonged duration local anesthesia with minimal toxicity
ES2484315T3 (es) 2010-02-10 2014-08-11 Phytotox Limited Tratamiento de la pérdida del sentido del tacto con derivados de saxitoxina
AU2011336467A1 (en) 2010-12-01 2013-07-04 Spinal Modulation, Inc. Agent delivery systems for selective neuromodulation
WO2014159595A2 (en) 2013-03-14 2014-10-02 Regeneron Pharmaceuticals, Inc. Human antibodies to nav1.7
PL3492075T3 (pl) 2013-03-15 2024-04-22 The Children's Medical Center Corporation Skojarzone postacie użytkowe neosaksytoksyny do znieczulenia miejscowego o przedłużonym działaniu
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
AU1888195A (en) * 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
AU6883798A (en) * 1997-04-02 1998-10-22 Regents Of The University Of California, The Method of anesthesia
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Also Published As

Publication number Publication date
EE200300106A (et) 2005-04-15
MXPA03002389A (es) 2004-03-12
BG107690A (bg) 2004-01-30
IL154342A0 (en) 2003-09-17
YU17103A (sh) 2006-03-03
KR20030034181A (ko) 2003-05-01
CA2421562A1 (en) 2002-03-21
NO20030915D0 (no) 2003-02-27
ZA200301852B (en) 2004-06-21
EP2298306B1 (en) 2013-09-11
WO2002022129A1 (en) 2002-03-21
SK3732003A3 (sk) 2005-05-05
KR100891568B1 (ko) 2009-04-03
CA2421562C (en) 2011-05-24
CN1356104A (zh) 2002-07-03
ATE447959T1 (de) 2009-11-15
DE60140466D1 (de) 2009-12-24
UA76960C2 (en) 2006-10-16
ES2435463T3 (es) 2013-12-19
KR20070112864A (ko) 2007-11-27
AU2002213785A1 (en) 2002-03-26
EP1320369A1 (en) 2003-06-25
EP1320369B1 (en) 2009-11-11
HRP20030202A2 (en) 2005-02-28
CN1284536C (zh) 2006-11-15
EA004870B1 (ru) 2004-08-26
EP1320369A4 (en) 2003-07-02
HUP0302677A3 (en) 2005-01-28
NO323960B1 (no) 2007-07-23
HUP0302677A2 (hu) 2003-11-28
BR0113961A (pt) 2004-01-13
JP2004508404A (ja) 2004-03-18
EP2298306A1 (en) 2011-03-23
ATE542534T1 (de) 2012-02-15
NO20030915L (no) 2003-04-25
US6407088B1 (en) 2002-06-18
EP1563839B1 (en) 2012-01-25
PL360616A1 (en) 2004-09-20
EP1563839A1 (en) 2005-08-17
IS6719A (is) 2003-02-14

Similar Documents

Publication Publication Date Title
EA200300172A1 (ru) Метод обезболивания
HK1091481A1 (en) Therapeutic agents useful for treating pain
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
TW200510375A (en) New compounds
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
MXPA05013587A (es) Agentes terapeuticos utiles para el tratamiento del dolor.
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
MX2009011601A (es) Agentes terapeuticos utiles para tratar el dolor.
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
MX2009005798A (es) Recuperacion de apoplejia.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
NO20051261L (no) Morfin-6-glukuronidsalt
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
SE0301884D0 (sv) New use III
EA200501818A1 (ru) Индазолы, обладающие анальгетической активностью
NI200700218A (es) Derivados de amida como ligandos de canales iónicos y composiciones farmacéuticas y métodos para usar los mismos.
DK1011672T3 (da) Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger
EA200500957A1 (ru) Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung